BACKGROUND: Little is known about the frequency of traumatic event exposure and the development of post-traumatic stress disorder (PTSD) among German soldiers serving in Afghanistan. METHODS: We studied a random sample consisting of 1599 soldiers who had served in the 2009/2010 ISAF mission in Afghanistan, stratified by deployment location and unit. Twelve months after their return to Germany, the soldiers were assessed with a Composite International Diagnostic Interview (CIDI) to establish the diagnoses of mental disorders and PTSD according to the DSM-IV. 889 similar soldiers who had not been deployed abroad were assessed in the same way. RESULTS: 49.2% (95% confidence interval [CI]: 46.4 to 52.1) of the deployed soldiers experienced at least one traumatic event during their deployment, and 13% experienced more than three. The 12-month prevalence of PTSD among returning soldiers was 2.9% (95% CI: 2.1 to 4.1), while the service-related incidence after deployment was 0.9% (95% CI: 0.5 to 1.6). These figures imply a two- to fourfold elevation of the risk of PTSD. The risk of PTSD was highest among soldiers who had served in Kunduz (Afghanistan) and in combat units. Only half of all soldiers with PTSD sought professional help. CONCLUSION: Deployment abroad is associated with a high frequency of traumatic experiences and a two- to fourfold elevation of the risk of PTSD. Each year, about 300 cases of PTSD develop for every 10 000 soldiers who return to Germany; thus, the cumulative number of returnees with PTSD from the beginning of German deployment abroad may currently run into the thousands. 45% of all PTSD cases, or about one in two, are neither diagnosed nor treated. Deployment abroad also substantially increases the risk of developing a number of other mental disorders.
BACKGROUND: Little is known about the frequency of traumatic event exposure and the development of post-traumatic stress disorder (PTSD) among German soldiers serving in Afghanistan. METHODS: We studied a random sample consisting of 1599 soldiers who had served in the 2009/2010 ISAF mission in Afghanistan, stratified by deployment location and unit. Twelve months after their return to Germany, the soldiers were assessed with a Composite International Diagnostic Interview (CIDI) to establish the diagnoses of mental disorders and PTSD according to the DSM-IV. 889 similar soldiers who had not been deployed abroad were assessed in the same way. RESULTS: 49.2% (95% confidence interval [CI]: 46.4 to 52.1) of the deployed soldiers experienced at least one traumatic event during their deployment, and 13% experienced more than three. The 12-month prevalence of PTSD among returning soldiers was 2.9% (95% CI: 2.1 to 4.1), while the service-related incidence after deployment was 0.9% (95% CI: 0.5 to 1.6). These figures imply a two- to fourfold elevation of the risk of PTSD. The risk of PTSD was highest among soldiers who had served in Kunduz (Afghanistan) and in combat units. Only half of all soldiers with PTSD sought professional help. CONCLUSION: Deployment abroad is associated with a high frequency of traumatic experiences and a two- to fourfold elevation of the risk of PTSD. Each year, about 300 cases of PTSD develop for every 10 000 soldiers who return to Germany; thus, the cumulative number of returnees with PTSD from the beginning of German deployment abroad may currently run into the thousands. 45% of all PTSD cases, or about one in two, are neither diagnosed nor treated. Deployment abroad also substantially increases the risk of developing a number of other mental disorders.
Authors: Nicola T Fear; Margaret Jones; Dominic Murphy; Lisa Hull; Amy C Iversen; Bolaji Coker; Louise Machell; Josefin Sundin; Charlotte Woodhead; Norman Jones; Neil Greenberg; Sabine Landau; Christopher Dandeker; Roberto J Rona; Matthew Hotopf; Simon Wessely Journal: Lancet Date: 2010-05-12 Impact factor: 79.321
Authors: Matthew Hotopf; Lisa Hull; Nicola T Fear; Tess Browne; Oded Horn; Amy Iversen; Margaret Jones; Dominic Murphy; Duncan Bland; Mark Earnshaw; Neil Greenberg; Jamie Hacker Hughes; A Rosemary Tate; Christopher Dandeker; Roberto Rona; Simon Wessely Journal: Lancet Date: 2006-05-27 Impact factor: 79.321
Authors: Dan J Stein; Marylene Cloitre; Charles B Nemeroff; David J Nutt; Soraya Seedat; Arieh Y Shalev; Hans-Ulrich Wittchen; Joseph Zohar Journal: CNS Spectr Date: 2009-01 Impact factor: 3.790
Authors: H U Wittchen; F Jacobi; J Rehm; A Gustavsson; M Svensson; B Jönsson; J Olesen; C Allgulander; J Alonso; C Faravelli; L Fratiglioni; P Jennum; R Lieb; A Maercker; J van Os; M Preisig; L Salvador-Carulla; R Simon; H-C Steinhausen Journal: Eur Neuropsychopharmacol Date: 2011-09 Impact factor: 4.600
Authors: S Trautmann; L Goodwin; M Höfler; F Jacobi; J Strehle; P Zimmermann; H-U Wittchen Journal: Epidemiol Psychiatr Sci Date: 2016-04-18 Impact factor: 6.892
Authors: Eric Kuhn; Christianne van der Meer; Jason E Owen; Julia E Hoffman; Richard Cash; Pasqualina Carrese; Miranda Olff; Anne Bakker; Julia Schellong; Patrick Lorenz; Matthias Schopp; Heinrich Rau; Kerstin Weidner; Filip K Arnberg; Martin Cernvall; Thomas Iversen Journal: Mhealth Date: 2018-05-25
Authors: David F Tate; Emily L Dennis; John T Adams; Maheen M Adamson; Heather G Belanger; Erin D Bigler; Heather C Bouchard; Alexandra L Clark; Lisa M Delano-Wood; Seth G Disner; Blessen C Eapen; Carol E Franz; Elbert Geuze; Naomi J Goodrich-Hunsaker; Kihwan Han; Jasmeet P Hayes; Sidney R Hinds; Cooper B Hodges; Elizabeth S Hovenden; Andrei Irimia; Kimbra Kenney; Inga K Koerte; William S Kremen; Harvey S Levin; Hannah M Lindsey; Rajendra A Morey; Mary R Newsome; John Ollinger; Mary Jo Pugh; Randall S Scheibel; Martha E Shenton; Danielle R Sullivan; Brian A Taylor; Maya Troyanskaya; Carmen Velez; Benjamin Sc Wade; Xin Wang; Ashley L Ware; Ross Zafonte; Paul M Thompson; Elisabeth A Wilde Journal: Brain Imaging Behav Date: 2021-01-07 Impact factor: 3.978
Authors: Peter Zimmermann; Susanne Firnkes; Jens T Kowalski; Johannes Backus; Stefan Siegel; Gerd Willmund; Andreas Maercker Journal: Eur J Psychotraumatol Date: 2014-05-05